Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like Particles (VLP) Quadrivalent Influenza Vaccine in the Elderly Population
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Medicago
- 23 Oct 2019 Status changed from active, no longer recruiting to completed.
- 09 May 2016 Planned End Date changed from 1 Sep 2015 to 1 Jun 2016.
- 24 Sep 2015 Planned End Date changed from 1 Jun 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.